Boehringer Ingelheim halts Iclepertin trials after failure to show efficacy Boehringer Ingelheim stops research on Iclepertin ...

Boehringer Ingelheim announced that its schizophrenia drug, iclepertin, did not achieve statistically significant ...

Boehringer Ingelheim announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia ...

Ingelheim, Germany Saturday, January 18, 2025, 11:00 Hrs [IST] ...

The company has said that all three of its CONNEX trials failed to meet expectations showing no significant impact on the patients living with the condition.

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and Human Services hit back on the pharma’s legal challenge to the IRA’s drug ...

German healthcare giant Boehringer Ingelheim has announced that its drug iclepertin, designed for patients living with cognitive impairment as a result of schizophrenia, has missed all primary and ...

Zeit Aktuelle Nachrichten 17.01. Boehringer drug for brain fog in schizophrenia fails trial 16.01. Boehringer's phase 3 schizophrenia program misses primary goal 16.01. Boehringer Ingelheim ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a trio of late-stage trials. The phase 3 program missed both primary ...